Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 Envelope protein

Journal of Virology

Volumn 76, Issue 6, 2002, Pages 2683-2691

  Edwards, Terri G ^a   Wyss, Stéphanie ^a   Reeves, Jacqueline D ^a   Zolla Pazner, Susan ^a   Hoxie, James A ^a   Doms, Robert W ^a   Baribaud, Frédéric ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY; NUCLEOTIDE; PROTEIN SUBUNIT; VIRUS VACCINE;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; BINDING SITE; CONTROLLED STUDY; FRAMESHIFT MUTATION; GENE DELETION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; QUAIL; RECEPTOR BINDING;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CONSERVED SEQUENCE; FRAMESHIFT MUTATION; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MEMBRANE FUSION; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY;

EID: 0036187805     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.6.2683-2691.2002     Document Type: Article

References (69)

1. Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor
2. Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation
3. Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity
4. The role of DC-SIGN and DC-SIGNR in HIV and SIV attachment, infection, and transmission
5. A membrane-proximal tyrosine-based signal mediates internalization of the HIV-1 envelope glycoprotein via interaction with the AP-2 clathrin adaptor
6. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals
7. Human monoclonal antibodies to the V3 loop of HIV-1 gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site
8. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41
9. HIV entry and its inhibition
10. Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by super-infection of nonproductively infected cell lines with recombinant luciferase-encoding viruses
11. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes
12. Quaternary structure of the influenza virus hemagglutinin after acid treatment
13. HIV-1 membrane fusion: Targets of opportunity
14. The plasma membrane as a combat zone in the HIV battlefield
15. Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity
16. Spontaneous mutations in the env gene of the human immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry phenotype
17. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein
18. Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein
19. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions
20. Effects of deletions in the cytoplasmic domain on biological functions of human immunodeficiency virus type 1 envelope glycoproteins
21. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1
22. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120
23. Sequence-specific antibodies show that maturation of Moloney leukemia virus envelope polyprotein involves removal of a COOH-terminal peptide
24. SIV adaptation to human cells
25. Stable exposure of the coreceptor binding site in a CD4-independent HIV-1 envelope protein
26. Retrovirus envelope glycoproteins
27. Significance of premature stop codons in env of simian immunodeficiency virus
28. Effect of the conformation of a peptide from gp41 on binding and domain formation in model membranes
29. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants
30. Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication
31. Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity
32. A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells
33. Evidence for cell-surface association between Fusin and the CD4-gp120 complex in human cell lines
34. Antigenic variation in gp120s from molecular clones of HIV-I LAI
35. Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail
36. The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions
37. Energetics of the HIV gp120-CD4 binding reaction
38. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane rafts
39. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M
40. Mutational analysis of conserved domains within the cytoplasmic tail of gp41 from human immunodeficiency virus type 1: Effects on glycoprotein incorporation and infectivity
41. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120
42. The construction and use of a human-mouse myeloma analogue suitable for the routine production of hybridomas secreting human monoclonal antibodies
43. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection
44. CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity
45. A role for carbohydrates in immune evasion in AIDS
46. Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120
47. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
48. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
49. Palmitoylation of the HIV-1 envelope glycoprotein is critical for viral infectivity
50. Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC
51. Cell-cell fusion assay to study the role of chemokine receptors in human immunodeficiency type 1 infection
52. An internalization signal in the simian immunodeficiency virus transmembrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surface
53. Intracellular transport of soluble and membrane-bound glycoproteins: Folding, assembly, and secretion of anchor-free influenza hemagglutinin
54. Effects of cytoplasmic domain length on cell surface expression and syncytium-forming capacity of the simian immunodeficiency virus envelope glycoprotein
55. Membrane interactions of synthetic peptides corresponding to amphipathic helical segments of the human immunodeficiency virus type-1 envelope glycoprotein
56. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding
57. CD4-dependent, antibody-sensitive interactions between HIV-1 and its coreceptor CCR-5
58. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
59. Interaction of a basic amphipathic peptide from the carboxyterminal part of the HIV envelope protein gp41 with negatively charged lipid surfaces
60. Theoretically determined three-dimensional structures for amphipathic segments of the HIV-1 gp41 envelope protein
61. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5
62. The antigenic structure of the HIV gp120 envelope glycoprotein
63. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens
64. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies
65. The human and simian immunodeficiency virus envelope glycoprotein transmembrane subunits are palmitoylated
66. Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions
67. Properties of wild-type, C-terminally truncated, and chimeric maedi-visna virus glycoprotein and putative pseudotyping of retroviral vector particles
68. Functional domains in the retroviral transmembrane protein
69. Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12